Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study

• Main Authors: Mónica López-Lacort (Author), Ana Corberán-Vallet (Author), Francisco J. Santonja (Author), Cintia Muñoz-Quiles (Author), Javier Díez-Domingo (Author), Alejandro Orrico-Sánchez (Author)
• Format: Book
• Published: Elsevier, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis...